Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies
Among the initial findings, some acromegaly patients managed by injectable somatostatin receptor ligands (SRLs) report symptoms that may interfere with daily life
Treatment burden associated with injectable SRLs underscores need for an alternative administered treatment option
Screening data generated from Chiasma’s ongoing MPOWERED™ randomized Phase 3 trial of its investigational octreotide capsules product candidate, conditionally trade-named, MYCAPSSA®
“For acromegaly patients with persistent disease following surgery, or for whom surgery is not an option, injectable somatostatin receptor ligands represent the current standard of care in the treatment of this rare but debilitating hormonal disorder,” commented
Details of the poster session are as follows:
Title: Symptom burden in patients with acromegaly treated with injectable somatostatin receptor ligands
Presenting author: Dr.
Poster #: 36 (late breaking abstract #242)
Date & time:
For more information on this poster presentation at GRS & IGF 2018, please visit: https://grs-igf2018.com/scientific/full-abstracts.aspx
This poster describes a method of assessing the ongoing symptoms and treatment burden of acromegaly patients receiving injectable somatostatin receptor ligands who are currently enrolled in Chiasma’s MPOWEREDTM global Phase 3, randomized, open-label study of its investigational octreotide capsule product candidate, which is conditionally trade-named MYCAPSSA®. Utilizing the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ), a patient-reported symptom assessment tool developed and copyrighted by Chiasma, data from 70 eligible patients were collected and analyzed. Among the findings:
- 66% of patients reported ongoing acromegaly symptoms, of which 83% reported some symptoms “all the time.”
- 50% indicated some symptoms worsen towards the end of the monthly injection interval.
- Symptoms interfered with daily life (91%) and leisure activities (86%).
- More than 50% reported GI side effects (median duration five days following each injection) that interfered with daily life.
- GI side effects were worse in patients with more active symptoms but did not correlate with IGF-1 levels or treatment dose.
Despite being biochemically-controlled, some patients managed by injectable SRLs report acromegaly symptoms that interfere with daily life. A majority of patients were satisfied with SRL treatment overall; however, non-injection SRL options are not currently available. Analyses should be replicated once all screening data are available to confirm these initial findings.
“These initial data, which were derived from screening data from Chiasma’s ongoing MPOWERED randomized Phase 3 trial of investigational octreotide capsules, highlight some of the deficiencies of the current standard of care associated with injectable SRLs concerning treatment burden,” continued Dr. Ludlam. “We are optimistic that oral octreotide capsules, if approved, represent a potential advancement in the maintenance treatment of adult patients with acromegaly, and we look forward to our planned report of topline data from both of our ongoing randomized Phase 3 trials, CHIASMA OPTIMAL in 4Q 2019 and MPOWERED by early 2020.”
About Chiasma’s MPOWERED™ Phase 3 Trial
Chiasma is conducting an international Phase 3 clinical trial under a protocol accepted by the
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company’s development of octreotide capsules, conditionally trade-named MYCAPSSA, for the maintenance treatment of acromegaly, the Company’s efforts to potentially obtain regulatory approval in
LifeSci Advisors, LLC